Company Overview

BioStem Technologies, Inc. is a regenerative medicine company focused on the development, manufacture, and commercialization of placental tissue–derived products used in advanced wound care and surgical applications. The company operates within the biotechnology and regenerative medicine industries, with a primary emphasis on biologic allografts derived from human placental tissue. Its core revenue is generated from the sale of proprietary amniotic membrane and fluid–based products used by healthcare providers.

The company’s primary customers include hospitals, wound care centers, outpatient clinics, and physicians specializing in wound management, ophthalmology, sports medicine, and surgical repair. BioStem’s strategic positioning is centered on vertically integrated manufacturing, regulatory compliance for human cell and tissue products, and scalable processing capabilities. The company traces its origins to BioD, Inc., which merged with Amnio Technology, LLC and subsequently rebranded as BioStem Technologies, Inc., marking its evolution into a focused regenerative medicine platform.

Business Operations

BioStem operates as a single-reportable segment focused on regenerative biologics, with substantially all revenue derived from placental tissue–based allograft products. Key product lines include dehydrated and cryopreserved amniotic membrane products marketed under brands such as Vendaje®, Vendaje AC®, and Vendaje Optic®, which are used primarily for chronic wound care and surgical applications. The company controls donor sourcing, processing, and distribution through its subsidiary Amnio Technology, LLC, enabling end-to-end operational oversight.

Operations are primarily domestic, with manufacturing and distribution conducted in the United States. BioStem relies on a direct sales force and distributor relationships to reach clinical customers. The company’s technologies are regulated under U.S. human tissue and cellular product frameworks, and revenue generation is tied closely to procedure volumes and adoption within wound care and surgical markets. Public disclosures indicate no material joint ventures; data inconclusive based on available public sources regarding minor partnerships.

Strategic Position & Investments

BioStem’s strategy emphasizes organic growth through increased penetration of advanced wound care markets, expansion of physician adoption, and continued development of placental-derived biologic products. The company has invested in manufacturing scale, quality systems, and compliance infrastructure to support growth and regulatory readiness. Strategic focus includes leveraging clinical data and real-world evidence to support broader use of its products.

A central strategic asset is Amnio Technology, LLC, which functions as BioStem’s operating and manufacturing subsidiary. Past acquisitions, including the integration of Amnio Technology, LLC, have shaped the company’s current structure and product portfolio. BioStem has disclosed interest in emerging regenerative applications, though specific investments in new technologies beyond placental biologics are not detailed in public filings; data inconclusive based on available public sources.

Geographic Footprint

BioStem Technologies is headquartered in Florida, with principal operations and manufacturing facilities located in the United States. The company’s commercial activities are concentrated in domestic healthcare markets, where regulatory clarity and reimbursement frameworks support its product offerings.

International operations are limited, with no material overseas manufacturing footprint disclosed in public filings. While products may reach non-U.S. clinicians through distributor channels, BioStem’s operational and investment influence remains predominantly within North America, and data is inconclusive regarding any significant international expansion initiatives.

Leadership & Governance

BioStem is led by an executive team with experience in regenerative medicine, biologics manufacturing, and healthcare commercialization. Leadership emphasizes operational discipline, regulatory compliance, and focused execution within defined clinical markets. The company is publicly traded and governed by a board responsible for strategic oversight and fiduciary compliance.

Key executives include:

• Jason Matuszewski – Chief Executive Officer
• Jason Matuszewski – President
• Jody Staggs – Chief Financial Officer (data inconclusive based on available public sources regarding tenure)
• Bob Rogers – Chief Operating Officer (data inconclusive based on available public sources)

The leadership philosophy centers on disciplined growth, vertical integration, and building a scalable regenerative medicine platform aligned with clinical demand and regulatory standards.